Study: DaT-SPECT Imaging Likely of Little Use in Trial Recruitment

Study: DaT-SPECT Imaging Likely of Little Use in Trial Recruitment

313552

Study: DaT-SPECT Imaging Likely of Little Use in Trial Recruitment

Nearly all participants in the SPARK clinical trial had evidence of abnormal dopamine activity on a brain scan known as DaT-SPECT, for dopamine transporter single-photon emission computed tomography, according to a new study. Thus, these results suggest that DaT-SPECT — sometimes used as a biomarker in recruiting participants for clinical studies — might not be needed to identify appropriate patients for future trials in Parkinson’s disease, the researchers said. “We suggest that decisions regarding the…

You must be logged in to read/download the full post.